.jpg "Aerie Pharma (NASDAQ: AERI)")
Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $77. The company’s shares closed yesterday at $45.82.
Yang wrote:
“We see this guidance as conservative and we believe there is a reasonable chance for Aerie to outperform in 2019. We currently model FY19 revenue of ~$120mn. Rocklatan is expected to launch in the U.S. in early May with a fully trained salesforce. Keep in mind: insurance coverage pickup could be faster as contracts with payers will already be in place (from Rhopressa).”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 19.3% and a 49.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $78.86, which is a 72.1% upside from current levels. In a report issued on February 26, Oppenheimer also maintained a Buy rating on the stock with a $64 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $74.75 and a one-year low of $32.18. Currently, Aerie Pharma has an average volume of 651.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan.
